Purple Biotech Ltd. (PPBT)
NASDAQ: PPBT
· Real-Time Price · USD
0.57
-0.01 (-1.30%)
At close: Sep 26, 2025, 10:57 AM
-1.30% (1D)
| Bid | 0.57 |
| Market Cap | 7.49K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.61M |
| EPS (ttm) | -45.9 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | -0.94 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 0.57 |
| Volume | 32,352 |
| Avg. Volume (20D) | 1,035,146 |
| Open | 0.57 |
| Previous Close | 0.58 |
| Day's Range | 0.56 - 0.58 |
| 52-Week Range | 0.53 - 13.95 |
| Beta | -0.51 |
| Ex-Dividend Date | n/a |
About PPBT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PPBT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PPBT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
-45.07%
Purple Biotech shares are trading lower after the ...
Unlock content with
Pro Subscription
3 weeks ago
+0%
PPBT stock has given up its prior loss. Purple Biotech shares were trading lower. The company announced its second CAPTN-3 trispecific antibody, targeting TROP2 in development.
